TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Entrada Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.82+0.45 (+10.30%)
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.6%
29M of 39M shares
Institutional holders
129
27 new, 16 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
17 buys · 44 sales
Net sold $13.46M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker | 4,865,819 | 13.20% | 13D (active) amendment | Jun 24, 2024 |
| Kush Parmar | 4,123,849 | 10.80% | 13D (active) amendment | Nov 14, 2025 |
| Ansbert Gadicke | 3,885,115 | 9.90% | 13D (active) amendment | Sep 8, 2026 |
| Roche Holding Ltd | 2,569,115 | 6.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 1,974,452 | 5.30% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 5,072,730 | 13.03% | $37.34M | – | 0.19% |
| 5AM Venture Management, LLC | 4,056,379 | 10.42% | $29.85M | – | 10.37% |
| BlackRock, Inc. | 2,583,333 | 6.63% | $19.01M | +224,540 | 0.00% |
| Merck & Co., Inc. | 1,739,768 | 4.47% | $12.80M | New | 2.43% |
| Vanguard Capital Management LLC | 1,269,634 | 3.26% | $9.34M | +13,621 | 0.00% |
| Mpm Bioimpact LLC | 1,253,053 | 3.22% | $9.22M | New | 0.56% |
| TCG Crossover Management, LLC | 1,060,230 | 2.72% | $7.80M | −1,227,270 | 0.19% |
| Wellington Management Group Llp | 954,419 | 2.45% | $7.02M | −80,363 | 0.00% |
| Millennium Management LLC | 763,959 | 1.96% | $5.62M | +244,603 | 0.00% |
| StepStone Group LP | 761,277 | 1.96% | $5.60M | – | 0.26% |
| Geode Capital Management, LLC | 717,430 | 1.84% | $5.28M | +50,083 | 0.00% |
| Aqr Capital Management LLC | 699,537 | 1.80% | $5.15M | +620,044 | 0.00% |
| Nantahala Capital Management, LLC | 601,150 | 1.54% | $4.42M | +441,818 | 0.07% |
| State Street Corp | 596,677 | 1.53% | $4.39M | +62,879 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 542,316 | 1.39% | $3.99K | +16,273 | 0.00% |
| JPMorgan Chase & Co | 496,457 | 1.28% | $3.83M | +481,610 | 0.00% |
| Acadian Asset Management LLC | 400,862 | 1.03% | $2.95K | +67,693 | 0.00% |
| Citadel Advisors LLC | 394,323 | 1.01% | $2.90M | +179,305 | 0.00% |
| Dimensional Fund Advisors LP | 376,136 | 0.97% | $2.77M | +51,665 | 0.00% |
| Northern Trust Corp | 309,942 | 0.80% | $2.28M | +74,950 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 129 | 29M | 75.6% | 27 / 55 | 31 / 16 | 7M | 3M |
| Q1 2026 | 119 | 25M | 65.4% | 20 / 46 | 33 / 13 | 4M | 1M |
| Q4 2025 | 113 | 24M | 62.8% | 16 / 35 | 42 / 15 | 3M | 2M |
| Q3 2025 | 116 | 29M | 73.5% | 26 / 49 | 28 / 16 | 4M | 5M |
| Q2 2025 | 106 | 30M | 76.0% | 22 / 45 | 23 / 26 | 1M | 2M |
| Q1 2025 | 110 | 30M | 77.7% | 20 / 27 | 43 / 11 | 1M | 1M |
| Q4 2024 | 102 | 31M | 78.8% | 19 / 43 | 24 / 14 | 2M | 1M |
| Q3 2024 | 97 | 30M | 77.3% | 22 / 41 | 19 / 8 | 3M | 1M |
| Q2 2024 | 84 | 30M | 76.3% | 18 / 42 | 11 / 9 | 5M | 1M |
| Q1 2024 | 77 | 26M | 67.4% | 18 / 19 | 23 / 3 | 1M | 1M |
| Q4 2023 | 62 | 26M | 67.7% | 10 / 23 | 13 / 3 | 1M | 0M |
| Q3 2023 | 55 | 26M | 66.9% | 4 / 19 | 14 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TRDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 953,727 | 2.45% | $7.02M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 768,028 | 1.97% | $5.65M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 322,233 | 0.83% | $2.19M | 0.01% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 295,981 | 0.76% | $2.18M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 283,038 | 0.73% | $2.08M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 271,022 | 0.70% | $1.99M | 0.01% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 175,405 | 0.45% | $1.29M | 0.12% | Jun 30, 2026 |
| iShares Biotechnology ETF | 150,880 | 0.39% | $1.11M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 145,785 | 0.37% | $1.03M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 127,190 | 0.33% | $899.23K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 113,479 | 0.29% | $802.30K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 108,498 | 0.28% | $736.70K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 98,852 | 0.25% | $727.55K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 71,947 | 0.18% | $488.52K | 0.01% | Jul 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 70,280 | 0.18% | $496.88K | 0.04% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dipal Doshi | CEO, Director | 517,290 | 1.33% | Sep 3, 2026 |
| Kory James Wentworth | Chief Financial Officer | 117,277 | 0.30% | Sep 3, 2026 |
| Natarajan Sethuraman | President, Research & Develop. | 214,238 | 0.55% | Sep 3, 2026 |
| Nathan J. Dowden | President & COO | 196,060 | 0.50% | Sep 3, 2026 |
| Kush Parmar | Director | 3,784,650 | 9.72% | Aug 10, 2026 |
| Maha Radhakrishnan | Director | – | – | Jun 12, 2026 |
| Peter S. Kim | Director | 117,412 | 0.30% | Jun 12, 2026 |
| Mary Thistle | Director | – | – | Jun 12, 2026 |
| Bernhardt G. Zeiher | Director | 5,000 | 0.01% | Jun 12, 2026 |
| Gina Chapman | Director | – | – | Jun 12, 2026 |
| BioVentures 2018 LLC MPM | 10% owner | 4,144,952 | 10.65% | Sep 9, 2026 |
| Mpm Bioventures 2018, L.P. | 10% owner | 4,325,784 | 11.11% | Sep 9, 2026 |
| BioVentures 2018 GP LLC MPM | 10% owner | 3,885,115 | 9.98% | Sep 9, 2026 |
| MPM BioVentures 2014 (B), L.P. | 10% owner | 4,231,434 | 10.87% | Sep 9, 2026 |
| Todd Foley | 10% owner | 4,318,348 | 11.09% | Sep 9, 2026 |
| BioVentures 2014 GP LLC MPM | 10% owner | 4,144,952 | 10.65% | Sep 9, 2026 |
| Asset Management Investors Bv2018 Llc Mpm | 10% owner | 4,381,062 | 11.25% | Sep 9, 2026 |
| Ansbert Gadicke | 10% owner | – | – | Sep 9, 2026 |
| Asset Management Investors BV2014 LLC MPM | 10% owner | 4,325,784 | 11.11% | Sep 9, 2026 |
| BioVentures 2014 LLC MPM | 10% owner | – | – | Sep 9, 2026 |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | 3,885,115 | 9.98% | Sep 9, 2026 |
| Luke Evnin | 10% owner | – | – | Sep 9, 2026 |
| MPM BioVentures 2014, L.P. | 10% owner | – | – | Sep 9, 2026 |
| 5AM Opportunities I (GP), LLC | 10% owner | – | – | Aug 10, 2026 |
| 5AM Ventures V, L.P. | 10% owner | 4,056,379 | 10.42% | Aug 10, 2026 |
| 5AM Partners V, LLC | 10% owner | – | – | Aug 10, 2026 |
| 5AM Opportunities I, L.P. | 10% owner | 4,256,379 | 10.93% | Aug 10, 2026 |
| Scott M. Rocklage | 10% owner | 3,877,094 | 9.96% | Aug 10, 2026 |
| Andrew J. Schwab | 10% owner | 4,283,379 | 11.00% | Aug 10, 2026 |
| Felix Baker | 10% owner | 380,152 | 0.98% | Nov 24, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| BioVentures 2018 GP LLC MPM 10% owner | Sep 9, 2026 | Sale | −28,837 | $7.13 | $205.61K | 3,885,115 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 9, 2026 | Sale | −28,837 | $7.13 | $205.61K | 3,885,115 |
| BioVentures 2018 GP LLC MPM 10% owner | Sep 8, 2026 | Sale | −192,500 | $7.41 | $1.43M | 3,913,952 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 8, 2026 | Sale | −192,500 | $7.41 | $1.43M | 3,913,952 |
| BioVentures 2018 GP LLC MPM 10% owner | Sep 4, 2026 | Sale | −38,500 | $7.11 | $273.74K | 4,106,452 |
| Mpm Bioventures 2018 (B), L.P. 10% owner | Sep 4, 2026 | Sale | −38,500 | $7.11 | $273.74K | 4,106,452 |
| BioVentures 2018 LLC MPM 10% owner | Sep 3, 2026 | Sale | −32,263 | $7.17 | $231.33K | 4,144,952 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 3, 2026 | Sale | −32,263 | $7.17 | $231.33K | 4,144,952 |
| Kory James Wentworth Chief Financial Officer | Sep 2, 2026 | Tax withholding | −1,733 | $7.14 | $12.37K | 117,277 |
| Nathan J. Dowden President & COO | Sep 2, 2026 | Tax withholding | −2,528 | $7.14 | $18.05K | 196,060 |
| BioVentures 2018 LLC MPM 10% owner | Sep 2, 2026 | Sale | −25,131 | $7.19 | $180.69K | 4,177,215 |
| Dipal Doshi CEO, Director | Sep 2, 2026 | Tax withholding | −8,724 | $7.14 | $62.29K | 517,290 |
| Natarajan Sethuraman President, Research & Develop. | Sep 2, 2026 | Tax withholding | −2,079 | $7.14 | $14.84K | 214,238 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 2, 2026 | Sale | −25,131 | $7.19 | $180.69K | 4,177,215 |
| BioVentures 2018 LLC MPM 10% owner | Sep 1, 2026 | Sale | −29,088 | $7.06 | $205.36K | 4,202,346 |
| BioVentures 2014 GP LLC MPM 10% owner | Sep 1, 2026 | Sale | −29,088 | $7.06 | $205.36K | 4,202,346 |
| BioVentures 2018 LLC MPM 10% owner | Aug 31, 2026 | Sale | −44,259 | $6.99 | $309.37K | 4,231,434 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 31, 2026 | Sale | −44,259 | $6.99 | $309.37K | 4,231,434 |
| BioVentures 2018 LLC MPM 10% owner | Aug 28, 2026 | Sale | −3,733 | $7.01 | $26.17K | 4,275,693 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 28, 2026 | Sale | −3,733 | $7.01 | $26.17K | 4,275,693 |
| BioVentures 2018 LLC MPM 10% owner | Aug 27, 2026 | Sale | −38,922 | $7.20 | $280.24K | 4,279,426 |
| MPM BioVentures 2014 (B), L.P. 10% owner | Aug 27, 2026 | Sale | −38,922 | $7.20 | $280.24K | 4,279,426 |
| BioVentures 2018 LLC MPM 10% owner | Aug 26, 2026 | Sale | −14,569 | $7.06 | $102.86K | 4,318,348 |
| Todd Foley 10% owner | Aug 26, 2026 | Sale | −14,569 | $7.06 | $102.86K | 4,318,348 |
| BioVentures 2018 LLC MPM 10% owner | Aug 25, 2026 | Sale | −26,522 | $7.54 | $199.98K | 4,332,917 |
| Todd Foley 10% owner | Aug 25, 2026 | Sale | −26,522 | $7.54 | $199.98K | 4,332,917 |
| BioVentures 2018 LLC MPM 10% owner | Aug 24, 2026 | Sale | −21,623 | $7.34 | $158.71K | 4,359,439 |
| Todd Foley 10% owner | Aug 24, 2026 | Sale | −21,623 | $7.34 | $158.71K | 4,359,439 |
| Kush Parmar Director | Aug 10, 2026 | Sale | −92,444 | $7.00 | $647.11K | 2,691,337 |
| Scott M. Rocklage 10% owner | Aug 7, 2026 | Sale | −52,317 | $6.85 | $358.37K | 2,783,781 |
| Kush Parmar Director | Aug 7, 2026 | Sale | −52,317 | $6.85 | $358.37K | 2,783,781 |
| Scott M. Rocklage 10% owner | Aug 6, 2026 | Sale | −10,494 | $7.00 | $73.46K | 2,836,098 |
| Kush Parmar Director | Aug 6, 2026 | Sale | −10,494 | $7.00 | $73.46K | 2,836,098 |
| Scott M. Rocklage 10% owner | Jul 31, 2026 | Sale | −1,718 | $6.85 | $11.77K | 2,846,592 |
| Kush Parmar Director, 10% owner | Jul 31, 2026 | Sale | −1,718 | $6.85 | $11.77K | 2,846,592 |
| Scott M. Rocklage 10% owner | Jul 30, 2026 | Sale | −114,756 | $6.93 | $795.26K | 2,848,310 |
| Kush Parmar Director, 10% owner | Jul 30, 2026 | Sale | −114,756 | $6.93 | $795.26K | 2,848,310 |
| Bernhardt G. Zeiher Director | May 20, 2026 | Buy | +5,000 | $5.86 | $29.30K | 5,000 |
| Natarajan Sethuraman President, Research & Develop. | May 4, 2026 | Sale(10b5-1 plan) | −25,907 | $15.39 | $398.71K | 216,317 |
| Nathan J. Dowden President & COO | May 4, 2026 | Sale(10b5-1 plan) | −15,000 | $15.33 | $229.95K | 198,588 |
| Nathan J. Dowden President & COO | May 4, 2026 | Option exercise | +15,000 | $1.74 | $26.10K | 213,588 |
| Kory James Wentworth Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −2,500 | $12.95 | $32.38K | 119,010 |
| Nathan J. Dowden President & COO | Mar 10, 2026 | Sale(10b5-1 plan) | −11,894 | $13.05 | $155.22K | 198,588 |
| Kory James Wentworth Chief Financial Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −11,388 | $13.02 | $148.27K | 121,510 |
| Nathan J. Dowden President & COO | Mar 9, 2026 | Sale(10b5-1 plan) | −3,116 | $13.02 | $40.57K | 210,482 |
| Kory James Wentworth Chief Financial Officer | Mar 9, 2026 | Sale(10b5-1 plan) | −5,089 | $13.00 | $66.16K | 132,898 |
| Kory James Wentworth Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −7,988 | $12.25 | $97.85K | 137,987 |
| Natarajan Sethuraman President, Research & Develop. | Mar 3, 2026 | Tax withholding | −7,577 | $11.76 | $89.11K | 242,224 |
| Dipal Doshi CEO, Director | Mar 3, 2026 | Tax withholding | −19,181 | $11.76 | $225.57K | 526,014 |
| Kory James Wentworth Chief Financial Officer | Mar 3, 2026 | Tax withholding | −5,712 | $11.76 | $67.17K | 145,975 |
| Nathan J. Dowden President & COO | Mar 3, 2026 | Tax withholding | −14,038 | $11.76 | $165.09K | 213,598 |
| Natarajan Sethuraman President, Research & Develop. | Mar 2, 2026 | Tax withholding | −3,898 | $11.66 | $45.45K | 249,801 |
| Dipal Doshi CEO, Director | Mar 2, 2026 | Tax withholding | −9,869 | $11.66 | $115.07K | 545,195 |
| Kory James Wentworth Chief Financial Officer | Mar 2, 2026 | Tax withholding | −2,939 | $11.66 | $34.27K | 151,687 |
| Nathan J. Dowden President & COO | Mar 2, 2026 | Tax withholding | −7,223 | $11.66 | $84.22K | 227,636 |
| Natarajan Sethuraman President, Research & Develop. | Mar 1, 2026 | Award | +55,800 | – | – | 253,699 |
| Dipal Doshi CEO, Director | Mar 1, 2026 | Award | +139,400 | – | – | 555,064 |
| Kory James Wentworth Chief Financial Officer | Mar 1, 2026 | Award | +44,600 | – | – | 154,626 |
| Nathan J. Dowden President & COO | Mar 1, 2026 | Award | +55,800 | – | – | 234,859 |
| Kory James Wentworth Chief Financial Officer | Nov 21, 2025 | Sale(10b5-1 plan) | −8,910 | $9.98 | $88.92K | 110,026 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. Affiliated stockholder | Aug 10, 2026 | 331,156 | $2.17M | Jul 30, 2026 | Venture Financing Investment |
| 5AM Ventures V, L.P. Affiliated stockholder | Jul 30, 2026 | 331,156 | $2.17M | Jul 30, 2026 | Venture Financing Investment |
| Dowden Nathan Officer | May 4, 2026 | 15,000 | $217.50K | May 4, 2026 | Exercise of Stock Options |
| Sethuraman Natarajan Officer | May 4, 2026 | 25,907 | $375.65K | May 4, 2026 | Restricted Stock Units |
| Wentworth Kory Officer | Apr 1, 2026 | 2,500 | $31.55K | Apr 1, 2026 | Previously Exercised Stock Options |
| Wentworth Kory Officer | Mar 9, 2026 | 16,477 | $207.28K | Mar 9, 2026 | Previously Exercised Stock Options |
| Dowden Nathan Officer | Mar 9, 2026 | 15,010 | $188.83K | Mar 9, 2026 | Restricted Stock Units |
| Wentworth Kory Officer | Mar 4, 2026 | 7,988 | $94.66K | Mar 4, 2026 | Restricted Stock Units |
| Wentworth Kory Officer | Nov 21, 2025 | 8,910 | $81.70K | Nov 21, 2025 | Restricted Stock Units |
| 5AM Ventures V, L.P. Affiliated Stockholder | Nov 14, 2025 | 200,000 | $1.76M | Nov 14, 2025 | Venture Financing Investment |
| 5AM Ventures V, L.P. Director | Jul 9, 2025 | 20,065 | $150.53K | Jul 9, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jul 9, 2025 | 6,935 | $52.03K | Jul 9, 2025 | Venture Investment |
| 5AM Ventures V, L.P. Director | Jul 1, 2025 | 18,578 | $132.32K | Jul 1, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jul 1, 2025 | 6,422 | $45.74K | Jul 1, 2025 | Venture Investment |
| 5AM Opportunities I, L.P. Director | Jun 30, 2025 | 6,422 | $43.75K | Jun 30, 2025 | Venture Investment |